Cognition Conversations

Featuring:Brendan Kelley, MD (moderator), UT Southwestern Medical Center, Professor and Clinical Vice Chair in the Department of NeurologySamantha K. Holden, MD, MS, FAAN, University of Colorado School of Medicine, Associate Professor of Neurology, Vice Chair for Outpatient Neurology ServicesCarla Preyer, Salon Owner, Inspirational Speaker, Care Partner to her Husband, PatrickLinda Szypula Ed.D., Science Teacher, Care Partner to her Husband, JamesIndex:0:00 Introduction2:00 Caregiver Distress and Symptom Burden16:14 Measuring Meaningful Changes in a Clinical Trial22:09 Closing remarks

Featuring: Anthony Caggiano, M.D., Ph.D. (moderator), Cognition Therapeutics, Chief Medical Officer James E. Galvin, MD, MPH, University of Miami, Director of the Comprehensive Center for Brain Health, Miller School of Medicine Lawrence S. Honig, MD, PhD, FAAN, Columbia University, Professor of Neurology, Irving Medical Center David Shprecher, D.O., Banner Sun Health Research Institute, Movement Disorder Director, Banner Sun HealthClinical Associate Professor, University of Arizona Index: 0:00 Introduction 0:45 Comparing Alzheimer’s disease and DLB 5:02 SHIMMER Design and Outcomes 10:22 Metrics for Success in a Signal-finding Study

Featuring: Anthony Caggiano, M.D., Ph.D. (moderator) Cognition Therapeutics, Chief Medical Officer Mary Hamby, Ph.D. (moderator) Cognition Therapeutics, Vice President of Research Everard (Jort) Vijverberg, MD, PhD Alzheimer Center at Amsterdam University Medical Center, Neurologist and CNS Trial Specialist Tara Spires Jones, DPhil University of Edinburgh, Personal Chair of Neurodegeneration and Deputy Director of the Centre for Discovery Brain Sciences Index: 0:00 Introduction 3:49 Findings from SEQUEL 6:45 Clinical observations of CT1812 engagement 9:08 Proteomic evidence of CT1812 engagement 11:52 CT1812’s ongoing Phase 2 study

Featuring: Anthony Caggiano, M.D., Ph.D. (moderator), Cognition Therapeutics, Chief Medical Officer Willem de Haan, M.D., Ph.D., Alzheimer Center at Amsterdam University Medical Center, Neurologist and Senior Researcher Philip Scheltens, M.D., EQT Life Sciences, Partner and Head of Dementia Fund, Former Director of the Alzheimer Center at Amsterdam University Medical Center Index: 0:00 Introduction 0:44 Rationale for the SEQUEL Study Design 2:10 EEG in neurodegenerative diseases 4:33 Findings from SEQUEL 9:52 Key Takeaways

Featuring: Anthony Caggiano, M.D., Ph.D., Chief Medical Officer, Cognition Therapeutics C. Gustavo De Moraes, M.D., Ph.D. (moderator), Chief Medical Officer, Ora (CRO), and Associate Professor of Clinical Ophthalmology, Columbia University Jeffrey S. Heier, M.D., Director of the Vitreoretinal Service & Retina Research, Ophthalmic Consultants of Boston Peter K. Kaiser, M.D., Chaney Family Endowed Chair in Ophthalmology Research and Professor of Ophthalmology, Cleveland Clinic Lerner College of Medicine

Featuring: Mary Hamby, Ph.D., Vice President of Research, Cognition Therapeutics Charlotte Teunissen, Ph.D. (moderator), Amsterdam University Medical Center, Professor of Clinical Neurochemistry Nicholas Seyfried, Ph.D., Emory University School of Medicine, Professor of Biochemistry and Neurology , Director of the Emory Integrated Proteomics Core Henrik Zetterberg, MD, Ph.D., Gothenburg University, Professor of Neuroscience Group Leader of the UK Dementia Research Institute Index: 0:00 Introduction 01:53 Utility of Proteomic Analysis in Alzheimer’ 03:20 Review of Proteomics Findings from AD/PD 202 08:36 Key Learnings

Featuring: Anthony Caggiano, M.D., Ph.D., Chief Medical Officer and Head of Research & Development, Cognition Therapeutics Brendan Kelley, M.D. (moderator), University of Texas SW, Vice Chair for Clinical Operations at the Peter O’Donnell Jr. Brain Institute and a Professor in the Department of Neurology Sarah B. Berman, M.D., Ph.D., University of Pittsburgh, Associate Professor in the Departments of Neurology and Clinical & Translational Science and Director of DLB Programs at the ARDC James Leverenz, M.D., Cleveland Clinic, Director of the Lou Ruvo Center for Brain Health David Shprecher, D.O., Banner Sun Health Research Institute, Movement Disorder Director University of Arizona, Clinical Associate Professor Index: 0:00 Introduction 01:09 Part I: The Intersection of Alzheimer’s and DLB 07:23 Biomarker Tests for DLB 09:11 Part II: Practical insights for community HCPs 09:40 Frequency of missed or delayed diagnosis of DLB 12:48 Facets of patient-reported memory loss 19:46 Nuances of psychological symptoms 24:23 Cognitive Fluctuations

Featuring: Lisa Ricciardi, President & Chief Executive Officer, Cognition Therapeutics Norma Loeb, Lewy Body Dementia Resource Center, Founder and Executive Director Mary Lou Falcone, M.L. FALCONE, Public Relations Board member, LBD Resource Center Author of “I Didn’t See It Coming, a Memoir of Love, Loss, and Lewy Body Dementia” Index: 0:00 Introduction 2:30 Key symptoms and signs of Lewy body dementia 9:44 The importance of an accurate diagnosis 13:30 Preparing for a doctor visit 15:30 Resources, support and caring for the caregiver

Featuring: Anthony Caggiano, M.D., Ph.D., Chief Medical Officer and Head of R&D, Cognition Therapeutics Christopher H. van Dyck, M.D., Yale University School of Medicine, Professor of Psychiatry, Neurology, and Neuroscience Director of the Division of Aging and Geriatric Psychiatry; Director of the Alzheimer’s Disease Research Center Anton P. Porsteinsson, M.D., University of Rochester School of Medicine and Dentistry, William B. and Sheila Konar Professor of Psychiatry, Neurology, Neuroscience, and Medicine Director of the Alzheimer’s Disease Care, Research and Education Program (AD-CARE) Index: 0:00 Introduction 1:47 Reactions to lecanemab results 3:48 Impact of targeting plaque 6:46 Potentially complementary strategies 11:24 Future of Alzheimer’s therapies 13:40 Conclusion

Featuring: Anthony Caggiano, M.D., Ph.D., Chief Medical Officer and Head of R&D, Cognition Therapeutics James Galvin, M.D., MPH, University of Miami Miller School of Medicine, Director of the Comprehensive Center for Brain Health Principal Investigator of the SHIMMER Study Index: 0:00 Introduction 1:09 What is DLB 3:13 Diagnostic Challenges 6:38 Potential Treatment Strategy 7:48 Designing a Clinical Trial 8:42 Conclusion